Alexandria Real Estate Equities
ARE
$0.00
+1.09%
Alexandria Real Estate Equities, Inc. is a specialized real estate investment trust (REIT) focused on developing, redeveloping, and operating high-quality properties leased to tenants in the life science, agtech, and technology sectors. The company is a dominant market leader in this niche, with a strategically concentrated portfolio in premier innovation clusters like Greater Boston, the San Francisco Bay Area, and New York City. The current investor narrative is dominated by the severe downturn in the broader office REIT sector, with ARE facing intense scrutiny over its fundamentals, including a significant year-over-year revenue decline and a large net loss reported in its latest quarter, raising questions about tenant demand and asset valuations in a challenging capital markets environment.…
ARE
Alexandria Real Estate Equities
$0.00
ARE 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alexandria Real Estate Equities's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
2 analysts
Implied Upside
—
vs. current price
Analyst Count
2
covering this stock
Price Range
$0 - $0
Analyst target range
Analyst coverage for ARE appears limited, with only 3 analysts providing estimates for future EPS and revenue, and no consensus price target or recommendation data provided in the analyst data set. This suggests insufficient analyst coverage to establish a reliable consensus view, which is typical for a company undergoing significant stress or for mid-cap stocks in out-of-favor sectors; the lack of targets implies higher uncertainty and less efficient price discovery. The available institutional ratings from recent months show a pattern of downgrades and neutral stances, including a notable downgrade from BMO Capital from 'Outperform' to 'Market Perform' in March 2026, while other firms like JP Morgan and Jefferies maintain 'Neutral' or 'Hold' ratings; this shift toward caution among the few covering analysts underscores the challenging fundamental backdrop and lack of near-term catalysts.
Bulls vs Bears: ARE Investment Factors
The bear case currently holds stronger evidence, anchored by the severe fundamental deterioration evidenced by a -$1.08 billion quarterly net loss and negative revenue growth. The bull case rests on the company's niche dominance, strong gross margins, and a valuation that appears to price in extreme pessimism. The single most important tension in the investment debate is whether the Q4 loss represents a one-time, non-cash impairment marking a bottom, or the beginning of a sustained period of operational decline and further asset value writedowns. The resolution of this tension—specifically, the trajectory of core funds from operations (FFO) and leasing spreads in upcoming quarters—will determine if the stock is a deep-value turnaround or a value trap.
Bullish
- Dominant Niche Leader in Life Science: ARE is the preeminent REIT focused on life science, agtech, and technology properties, with a portfolio concentrated in premier innovation clusters like Greater Boston and San Francisco. This specialization provides a structural advantage over generic office REITs, as demand for lab space is driven by long-term biotech R&D cycles rather than general office trends.
- Strong Gross Margin and FCF Generation: Despite severe profitability issues, the company maintains a robust gross margin of 69.18% and generated positive free cash flow of $1.41 billion on a TTM basis. This indicates the underlying rental business is fundamentally sound, with the massive Q4 net loss driven by non-cash impairments rather than operational cash burn.
- Manageable Debt and Balance Sheet: The debt-to-equity ratio of 0.82 is relatively conservative for a REIT, suggesting the company is not over-leveraged. This provides a buffer against further asset value declines and reduces refinancing risk in a challenging capital environment.
- Deep Valuation Discount to History: The stock trades at a PS ratio of 2.81, a dramatic collapse from historical levels above 11.0. This extreme de-rating, coupled with the price sitting just 7.3% above its 52-week low, suggests most negative sentiment is priced in, creating a potential valuation floor.
Bearish
- Severe Profitability Collapse: The company swung to a catastrophic net loss of -$1.08 billion in Q4 2025, resulting in a net margin of -143.4%. This loss, primarily from asset impairments, signals deep distress in the underlying property valuations and raises existential questions about earnings power.
- Revenue Decline and Negative Growth: Q4 2025 revenue of $754.4 million declined 1.16% YoY, marking a reversal from prior growth. For a REIT, negative revenue growth indicates potential tenant departures, lease expirations, or rent reductions, directly threatening the core business model.
- Extreme Technical Downtrend: The stock is down 38.10% over the past year, underperforming the S&P 500 by over 61 percentage points, and trades 48.0% below its 52-week high. This persistent selling pressure, with a 1-month relative strength of -9.06, indicates strong institutional outflow and a lack of buyer conviction.
- Analyst Downgrades and Low Coverage: Recent analyst actions include a downgrade from BMO Capital to 'Market Perform', with others maintaining neutral stances. With only 3 analysts providing estimates, there is limited institutional support and high uncertainty, typical for a distressed, out-of-favor sector.
ARE Technical Analysis
The stock is entrenched in a severe and sustained downtrend, with a 1-year price change of -38.10% as of the latest data, significantly underperforming the broader market. Currently trading at $45.84, the price sits just 7.3% above its 52-week low of $39.41 and 48.0% below its 52-week high of $88.24, positioning it deep in the lower portion of its annual range, which signals extreme bearish momentum and potential distress rather than a simple value opportunity. Recent momentum shows continued weakness, with the stock down 5.74% over the past month and down 15.36% over the past three months, a deceleration that aligns with and reinforces the longer-term negative trend; this persistent selling pressure is further evidenced by a 1-month relative strength of -9.06 against the S&P 500. Key technical support is clearly defined at the 52-week low of $39.41, while resistance is far overhead near the 52-week high of $88.24; a breakdown below the $39.41 support would signal a new leg down, while any recovery would face formidable resistance in the mid-$50s based on recent price action. With a beta of 1.14, the stock exhibits moderately higher volatility than the market, which is amplified during this pronounced downtrend, necessitating careful risk management for any potential position.
Beta
1.14
1.14x market volatility
Max Drawdown
-53.8%
Largest decline past year
52-Week Range
$39-$88
Price range past year
Annual Return
-29.5%
Cumulative gain past year
| Period | ARE Return | S&P 500 |
|---|---|---|
| 1m | +3.7% | +4.4% |
| 3m | -9.8% | +8.5% |
| 6m | -5.0% | +9.7% |
| 1y | -29.5% | +28.8% |
| ytd | -1.2% | +9.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ARE Fundamental Analysis
Revenue growth has turned negative, with Q4 2025 revenue of $754.4 million representing a year-over-year decline of 1.16%, a stark reversal from the positive growth seen in prior quarters of 2024; this deceleration to negative growth is a critical red flag for a REIT, indicating potential leasing challenges or tenant issues. The company's profitability has deteriorated dramatically, swinging from a net income of $167.9 million in Q3 2024 to a massive net loss of -$1.08 billion in Q4 2025, with the gross margin remaining relatively stable at 69.18% but being overwhelmed by other expenses, leading to a net margin of -143.4% for the quarter. The balance sheet and cash flow present a mixed picture: while the company generated positive free cash flow of $141.4 million on a TTM basis and maintains a manageable debt-to-equity ratio of 0.82, the quarterly operating cash flow of $312.4 million in Q4 2025 was insufficient to cover the period's substantial net loss, and the current ratio of 0.43 indicates potential liquidity strain in meeting short-term obligations.
Quarterly Revenue
$754414000.0B
2025-12
Revenue YoY Growth
-0.01%
YoY Comparison
Gross Margin
+0.69%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ARE Overvalued?
Given the company's deeply negative net income of -$1.08 billion for the latest quarter, the primary valuation metric selected is the Price-to-Sales (PS) ratio, as earnings-based multiples are not meaningful. The trailing PS ratio stands at 2.81, while the forward PS ratio is not explicitly provided but can be inferred from analyst revenue estimates; the market is applying a sales multiple that reflects the severe challenges in the office/life science real estate sector. Peer comparison data for the REIT - Office industry is not available in the provided dataset, preventing a direct sector premium/discount analysis; however, the current PS ratio of 2.81 is likely at a significant discount to historical norms given the stock's precipitous decline. Historically, the stock's own valuation has collapsed, with its PS ratio falling from levels above 11.0 in Q4 2025 (as per historical ratios data) to the current 2.81, indicating the market has drastically re-rated the company's sales multiple downward due to fundamental deterioration and sector-wide de-rating, placing it near the bottom of its own historical band.
PE
-5.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -441x~695x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
57.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on profitability collapse and liquidity. The massive Q4 net loss of -$1.08 billion, resulting in a net margin of -143.4%, is not merely an accounting event but reflects real impairment of asset values, suggesting the portfolio may be overvalued on its books. While free cash flow remains positive, the current ratio of 0.43 signals potential strain in covering short-term liabilities, which could force asset sales at distressed prices. Furthermore, the shift to negative revenue growth (-1.16% YoY) raises the risk of a downward spiral in occupancy and rental income, the lifeblood of any REIT.
Market & Competitive Risks are dominated by the sector-wide de-rating of office and life science real estate. The stock's PS ratio has collapsed from over 11.0 to 2.81, indicating the market has drastically re-rated the entire business model. With a beta of 1.14, ARE is more volatile than the market, amplifying losses during sector-wide selloffs. Competitive risks include potential overbuilding in life science clusters and the remote-work trend potentially reducing demand for specialized lab space, though this is mitigated by ARE's premier locations. The lack of analyst coverage (only 3 analysts) increases information asymmetry and price volatility.
Worst-Case Scenario involves a continuation of the current downtrend, where further asset impairments lead to covenant breaches, forcing a dilutive equity raise or a dividend suspension beyond the current low yield of 1.09%. Tenant demand evaporates in a biotech funding winter, causing occupancy to plummet and accelerating revenue declines. In this scenario, the stock could breach its 52-week low support of $39.41 and re-test levels implied by a PS ratio near 2.0, suggesting a realistic downside of approximately -20% to -30% from the current $45.84 price, potentially reaching the mid-$30s. The maximum drawdown of -53.79% shows such severe losses are within recent historical precedent.